Omixon Migrates CE 694131 Certificate from BSI UK to BSI NL

26/02/2019

We are pleased to inform our customers that Omixon has successfully upgraded its ISO Certificate according to ISO 13485:2016 standard and migrated its EC Certificate from the BSI UK Notified Body (ID: 0086) to the BSI NL Notified Body (ID: 2797). Our updated EC Certificate – Full Quality Assurance...

Mortality Prediction Hidden in our Genome

26/02/2019

The success of hematopoietic stem cell transplant (HSCT) is influenced by many factors including HLA mismatches, variations in the major histocompatibility complex (MHC) region, minor histocompatibility targets of allorecognition, regulatory elements that affect gene expression and genetic variation that affects immune responses (Table 1, Table 2). The individual contribution...

Omixon to Sponsor EWIC 2019 Conference with Scientific Talk

11/02/2019

Omixon is proud to announce that we are one of the Silver Sponsors of the Annual EWIC 2019 Conference. Libor Kolesár (Senior Field Application Scientist) and Nina Lauterbach (Field Application Scientist) will announce improvements to the existing products and an interesting talk by Mette Christiansen from Aarhus University. Title of...

THIS IS US: A Letter from CEO, Dr. Peter Meintjes

31/01/2019

Dear Customers and Friends of Omixon, Cue the emotion-grabbing drawn-out string music, cue the slow motion, zoomed-in camera shots focused on faces to capture the true depth of the feelings of the moment, and cue the hazy image filters that send you into the story telling time machine of...

Holotype HLA Validation on Illumina’s MiniSeq

31/01/2019

Introduction The Illumina NGS sequencing fleet includes instruments of different sample capacity. One of them is the MiniSeq – designed for laboratories with a small to medium sample throughput. Omixon’s Holotype HLA was initially developed and validated for Illumina’s MiSeq, as this is a commonly available instrument in clinical...